Beta Bionics (NASDAQ:BBNX) Insider Sells $16,420.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 821 shares of the firm’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $20.00, for a total value of $16,420.00. Following the transaction, the insider owned 54,513 shares of the company’s stock, valued at approximately $1,090,260. The trade was a 1.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total value of $13,446.25.
• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total value of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total value of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $101,798.97.

Beta Bionics Price Performance

NASDAQ BBNX opened at $16.75 on Friday. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The business has a 50 day simple moving average of $19.11 and a two-hundred day simple moving average of $14.89. The stock has a market capitalization of $910.65 million, a PE ratio of -9.10 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.01. The business had revenue of $35.51 million for the quarter. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. On average, analysts anticipate that Beta Bionics, Inc. will post -2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BBNX shares. William Blair assumed coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating for the company. UBS Group restated a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a report on Tuesday, September 15th. Leerink Partners upped their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $24.00 price target (up from $20.00) on shares of Beta Bionics in a report on Wednesday. Finally, Bank of America increased their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and an average price target of $23.69.

Institutional Trading of Beta Bionics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its position in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after acquiring an additional 240,000 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Beta Bionics during the 2nd quarter worth about $52,340,000. Bank of New York Mellon Corp purchased a new position in shares of Beta Bionics during the 2nd quarter worth about $1,926,000. Squarepoint Ops LLC bought a new position in Beta Bionics during the 2nd quarter valued at about $2,524,000. Finally, Bruce & Co. Inc. bought a new position in Beta Bionics during the 1st quarter valued at about $5,518,000.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Quarterly results slightly beat expectations. Beta Bionics reported a third-quarter loss of $0.52 per share, better than the $0.53 consensus estimate, while revenue of $35.51 million exceeded analysts’ expectations of approximately $34.7 million. The company also updated its 2026 guidance, although details were not provided. Beta Bionics third-quarter results
• Positive Sentiment: Analyst sentiment remains generally favorable. Stifel Nicolaus maintained a Buy rating, and several firms have raised price targets. MarketBeat data shows a Moderate Buy consensus and an average target of $23.69, above the recent trading level.
• Neutral Sentiment: Institutional ownership news was mixed but included notable purchases. BlackRock, Bank of America and other investment firms recently initiated or increased positions in Beta Bionics. Such activity may provide some support, but the reported purchases largely reflect earlier quarters rather than a new catalyst.
• Neutral Sentiment: Insiders continued to sell relatively small portions of their holdings. Director Mark Hopman sold 821 shares for about $16,420, while insider Mike Mensinger sold 2,650 shares for approximately $58,300. Both retained substantial positions, limiting the significance of the transactions, though repeated insider selling can weigh on investor sentiment. SEC insider filing
• Negative Sentiment: Multiple law firms reiterated a securities class-action deadline of November 3, 2026. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026. The unusually large number of investor-law-firm notices increases legal, reputational and potential financial risks for Beta Bionics.
• Negative Sentiment: The allegations center on FDA compliance and iLet safety disclosures. Notices allege that Beta Bionics did not fully disclose information related to an FDA warning, quality-system issues and more than 18,000 iLet complaints, including potentially serious hypoglycemia incidents. These claims have not been proven, but possible litigation costs, regulatory action or additional product concerns could pressure the stock. Beta Bionics securities class action notice
• Negative Sentiment: Execution risks could cloud future growth. The company has disclosed challenges associated with the commercial launch of its next-generation Mint patch pump, adding uncertainty to its growth outlook.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.